Evaluation of NTHL1, NEIL1, NEIL2, MPG, TDG, UNG and SMUG1 genes in familial colorectal cancer predisposition by Broderick, Peter et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Evaluation of NTHL1, NEIL1, NEIL2, MPG, TDG, UNG and SMUG1 
genes in familial colorectal cancer predisposition
Peter Broderick, Tina Bagratuni, Jairam Vijayakrishnan, Steven Lubbe, 
Ian Chandler and Richard S Houlston*
Address: Section of Cancer Genetics, Brookes Lawley Building, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
Email: Peter Broderick - peter.broderick@icr.ac.uk; Tina Bagratuni - tina.bagratuni@icr.ac.uk; 
Jairam Vijayakrishnan - jairam.vijayakrishnan@icr.ac.uk; Steven Lubbe - steven.lubbe@icr.ac.uk; Ian Chandler - ian.chandler@icr.ac.uk; 
Richard S Houlston* - richard.houlston@icr.ac.uk
* Corresponding author    
Abstract
Background: The observation that germline mutations in the oxidative DNA damage repair gene
MUTYH cause colorectal cancer (CRC) provides strong evidence that dysregulation of the base
excision repair (BER) pathway influences disease susceptibility. It is conceivable that germline
sequence variation in other BER pathway genes such as NTHL1, NEIL1, NEIL2, MPG, TDG, UNG and
SMUG1 also contribute to CRC susceptibility.
Methods: To evaluate whether sequence variants of NTHL1, NEIL1, NEIL2, MPG, TDG, UNG and
SMUG1 genes might act as CRC susceptibility alleles, we screened the coding sequence and intron-
exon boundaries of these genes in 94 familial CRC cases in which involvement of known genes had
been excluded.
Results: Three novel missense variants were identified NEIL2 C367A, TDG3 A196G and UNG2
C262T in patients, which were not observed in 188 healthy control DNAs.
Conclusion: We detected novel germline alterations in NEIL2, TDG and UNG patients with CRC.
The results suggest a limited role for NTHL1, NEIL1, NEIL2, MPG, TDG, UNG and SMUG1 in
development of CRC.
Background
A recent twin study indicates that approximately a third of
all colorectal cancers (CRC) involve an inherited predis-
position [1]. Germline mutations in the known CRC
genes (APC, mismatch repair (MMR) genes, MUTYH/
MYH, SMAD4, ALK3 and STK11/LKB1) do not, however,
account for all of the familial risk of the disease. The
observation that mutations in MUTYH predispose to CRC
[2,3]has provided strong evidence that dysregulation of
the base excision repair (BER) pathway contributes to dis-
ease susceptibility. MUTYH functions as a DNA glycosy-
lase responsible for excision of adenines mis-incorporated
opposite 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-
oxoG), a stable product of oxidative DNA damage [4]. The
BER pathway plays a pivotal role in protecting against oxi-
dative DNA damage and is especially relevant in colorec-
tum, which is characterised by high levels of oxygen
radicals generated by bacteria and dietary carcinogens
[5,6].
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In addition to MUTYH a number of other DNA glycosy-
lases participate in BER. These include endonuclease III-
like 1 (NTHL1, MIM 602556) which acts on oxidized pyri-
midine residues; endonuclease VIII-like 1 (NEIL1, MIM
608844) and endonuclease VIII-like 2, (NEIL2, MIM
608933) which initiate the first step in BER by cleaving
reactive oxygen species (ROS) damaged bases; N-methyl-
purine DNA glycosylase (MPG; MIM 156565) which
removes a diverse group of damaged bases, including
cytotoxic and mutagenic alkylation adducts of purine;
thymine-DNA glycosylase (TDG, MIM 601423) which ini-
tiates repair of G/T and G/U mismatches, commonly asso-
ciated with CpG islands, by removing thymine and uracil
moieties; uracil-DNA glycosylase (UNG, MIM 191525)
which removes uracil in DNA resulting from deamination
of cytosine or replicative incorporation of dUMP, and sin-
gle-strand-selective monofunctional uracil-DNA glycosy-
lase 1 (SMUG1; MIM 607753) which removes uracil from
single- and double-stranded DNA in nuclear chromatin.
To evaluate whether germline variants of NTHL1, NEIL1,
NEIL2, MPG, TDG, UNG and SMUG1 genes might act as
CRC susceptibility alleles, we have screened the coding
sequence and intron-exon boundaries of these genes in 94
familial CRC cases.
Methods
Ascertainment of cases and controls
Study subjects were ascertained as part of the National
Study of Colorectal Cancer (NSCCG). Details of the
NSCCG study design are available online [7,8]. Briefly,
the NSCCG was established in March 1999 and is an
ongoing study to investigate the role of genetic factors in
the aetiology of CRC. To date over 6,000 cases with histo-
logically verified adenocarcinoma of the colon or rectum
have been recruited from clinics throughout the United
Kingdom. A standardised questionnaire was used to col-
lect phenotypic and family history information from cases
and all were asked to provide blood samples for the
extraction of DNA. The current study is based on CRC
cases that reported family history of CRC in at least one
first-degree relative. The 94 cases with the earliest age of
CRC were selected. No cases carried biallelic MUTYH
mutations or a truncating mutation in APC (associated
with familial adenomatous polyposis). Germline mis-
match repair gene mutations were excluded by microsat-
ellite instability testing (BAT25, BAT26) in archival
tumour specimens. Although not totally comprehensive it
provides a relatively robust method of excluding inherited
MMR mutations. Controls were cancer free individuals
who were spouses or friends of cancer cases selected to
match the sex and age of the cases as closely as possible.
All study subjects were Caucasian of British ancestry and
current UK residents. Genomic DNA was extracted and
quantified from the venous blood samples by standard
methods.
Informed consent was obtained from all participants and
the study was undertaken with local ethical board
approval in accordance with the tenets of the Helsinki
Declaration.
Mutational analysis
The coding regions and intron-exon boundaries of
NTHL1,  NEIL1,  NEIL2,  MPG,  TDG,  UNG  and  SMUG1
were PCR amplified. Amplifying primers were designed
using the genomic sequence for each gene [9] in conjunc-
tion with Primer3 software [10]. Primer sequences and
PCR conditions for each gene are detailed in Table 3. PCR
products were hybridised and heteroduplexes assayed for
small intragenic mutations by conformation sensitive gel
electrophoresis (CSGE) [11]. Genomic DNA from cases
showing mobility shifts was sequenced using the BigDye-
Terminator Cycle Sequencingkit and a 3730xl automated
sequencer (Applied Biosystems, Foster City, USA). All
mutations were confirmed by sequencing at least two
independent PCR products.
Bio-informatics analysis
We applied two in silico algorithms, the PolyPhen algo-
rithm [12,13] and the SIFT algorithm [14,15], to predict
the putative impact of missense variants on protein func-
tion.
Results
DNAs from the 94 familial CRC without germline muta-
tions in the known CRC predisposition loci were screened
for sequence variants in NTHL1,  NEIL1,  NEIL2,  MPG,
Table 1: NTHL1, NEIL1, NEIL2, MPG, TDG, UNG and SMUG1 gnes screened for germline mutations.
Gene Genimic sequence cDNA sequence No. of exons No. of PCR fragements
NTHL1 NT_037887 NM_002528.4 6 7
NEIL1 NT_010194 NM_024608.1 9 11
NEIL2 NT_077531 NM_145043.1 4 6
MPG NT_037887 NM_002434.2 4 8
TDG NT_019546 NM_003211.3 10 12
UNG NT_009775 NM_080911.1 7 9
SMUG1 NT_029419 NM_014311.1 2 5BMC Cancer 2006, 6:243 http://www.biomedcentral.com/1471-2407/6/243
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TDG, UNG and SMUG1. The average age at diagnosis of
CRC in the cases was 54.8 years (SD, 9.3 years; median age
56 years). Of the cases 59 had been diagnosed with
colonic disease and 54 were male.
In total 22 sequence variants were identified (Table 2).
Eleven of the variants were detected in intronic (not
involving consensus splice sites) or untranslated regions.
One variant, rs5745908 maps to the second base of the
donor splice site in intron 1 of NEIL1. Of these twelve var-
iants, ten have been previously reported as polymor-
phisms (sequence variants with minor allele frequency
greater or equal to 1%) in the dbSNP database [16]. On
the basis of the likely absence of effect on protein function
and the fact that most were seen in multiple cases, we con-
sider it unlikely that these intronic variants represent
high-risk CRC cancer susceptibility alleles. Therefore,
these were not additionally investigated. Ten exonic vari-
ants were identified. None of the variants caused transla-
tional frameshifts or nonsense codons and three were
synonymous (i.e. maintaining the amino acid sequence of
the translated protein; Table 2). Of the three synonymous
variants, two were known polymorphisms documented in
dbSNP and only one was a novel change. Seven non-syn-
onymous changes were identified and of these four were
documented in dbSNP as polymorphisms. To investigate
the population frequency of the three novel missense
alterations identified in single unrelated cases (NEIL2
C367A,  TDG3  A196G and UNG2  C262T) the relevant
exons were screened in 188 cancer-free controls. None of
these variants were detected in the controls. The three
novel missense variants detected in familial CRC cases
were predicted to be probably damaging by both the
Polyphen and SIFT algorithms. NEIL2  C367A was
detected in a 65-year-old male with CRC. The individual's
brother, sister and nephew had also been diagnosed with
CRC. Variant TDG3 A196G was identified in a 66-year-old
male with rectal cancer. The patient's sister died of CRC at
age 47. Variant UNG2 C262T was identified in a male
with colonic cancer diagnosed at age 53 whose mother
and maternal aunt had CRC diagnosed at age 77 and 72
respectively. Unfortunately for reasons of clinical govern-
ance we were not in a position to evaluate tumour blocks
from relatives to test for segregation of alleles.
Table 2: Sequence changes in BER genes in familial colorectal cancer cases and controls
Gene  Exon Nucleotide change Amino acid change No. of heterozygote 
cases (n = 94)
No. of heterozygote 
controls (n = 188)
DbSNP 
database entry
NEIL1 IVS1 T434+2C 1 rs5745908
NEIL2 IVS1 T138+25C >10 rs804269
IVS1 C138+35T >10 rs804268
2 G308A R103Q 1 rs8191613
2 C367A P123T 1 0
3 A564G >10 rs8191642
IVS3 C689-13T >10 rs8191663
4   G770T   R257L 1   rs8191664  
3' UTR C999+21T >10 rs1534862
3'UTR 999+34 delC >10 rs8191667
MPG 5' UTR 1–27 insT 1 rs3176380
2 C147G 3 rs2259275
3C 3 4 2 G 1
TDG IVS2 A166+12G 4 rs3829300
IVS2 G167-9A >10 rs3751209
IVS2 G167-19C 1
3A 1 9 6 G R 6 6 G 1 0
10 G1099 A V367M >10 rs2888805
UNG 2 C262T R88C 1 0
2 G246C 0 1
IVS4 533–25 >10 rs3219235
IVS6 801+20 delTTTT >10
SMUG1 1 G44T G15V 1 rs2233920BMC Cancer 2006, 6:243 http://www.biomedcentral.com/1471-2407/6/243
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Table 3: Sequences of primers and PCR conditions used to screen BER genes.
Primer sequence (5' > 3')
Gene Fragment Forward Reverse Amplicon (bp) PCR Conditions*
NTHL1 1 GTAGTTCTGTGCCGCCCTCT CAGCCTGCAGCCCCTATC 270 68–60 TD, 1.7M B
2A ATGAACGAGTGAGGGGTGAG AGCTGTTGCTGCCAGTCC 244 68–60 TD, 1.7M B
2B AGAGACTGCGTGTGGCCTAT GAGGGTGCCAGCCAAAAG 284 68–60 TD, 1M B
3 CAGGGAATCACCCAGGAC AGGTCTCTCTCAGGCCACTG 279 68–60 TD, 1M B
4 GCTGCATCCTCCCAGGTT CACAGGTCACAAGGATGTGG 298 68–60 TD
5 GGCTAGGCTGGTGGAGTGT GGGTCAGTGCTGACAGAGG 225 68–60 TD
6 GGCTTCCTAGGGAGAAGAGC GTGGCTTCCTGAAGCGTAAA 266 68–60 TD
NEIL1 1A CAGCCGCTACCTCACAAAGT GCTGAAGCTGAGATGCGGTA 232 68–60 TD
1B CAGCCAGTTTGTGAATGAGG CCGTGTAAAAGCGCAGGT 281 68–60 TD
1C CCACTGGCCCTGGTCTTC TTGGCCAAGAAGGCACTAAG 295 68–60 TD, 1M B
2 AGGTTCTCTGAGCCCCTCTC GCTAGGCAGTGGGGAATGT 263 68–60 TD
3 GTGCCCACATTCCCCACT CTAAGCTGGGGACACCTGAC 208 68–60 TD
4 CCCAAAGTCTGACCAAGCTC CCCCAGGGTTACACAATCAT 245 68–60 TD
5 GAGCCTGCCCTCTGATCTCT GGGGTCTCTGCCTGTGTG 203 68–60 TD
6 CACTGATCTGGATGGGTGTG ATAGGGTGGAGAAGGGTGCT 210 60–50 TD, 1M B
7 AGCACCCTTCTCCACCCTAT CCGCCCTCTTAGGGTAAGG 238 68–60 TD
8 CCAACCTCTGAACTGCTTTCT TAGAGCCAGTTTCTGGGAGTG 257 68–60 TD
9 CGTGTACAAAGGTGGGAGAAA AATTCAGACCCCCAGATGC 216 68–60 TD
NEIL2 1 TGCTTGGCACCTGTTAAAGA CCCTGAGACATATGGGGATAGA 296 68–60 TD, 1M B
2A AATATCCGCATTCCCCAGTT GGGCGTCTCTCTCCAAATAC 296 68–60 TD, 1M B
2B GGGCAGAAGACCCTTGATG TGACTATCAGAGCCCACGAA 254 68–60 TD, 1M B
3 CAGCCACAGGGTGTGCTCT TCTGTGGACTCACCCCTTTC 299 68–60 TD, 1M B
4A GCCATGTGTCCTTTGTCCTT GCCTCTGTAACCCATCTTCG 290 68–60 TD, 1M B
4B CGCAGCACACACAGGTCTAC CCACATCCTCCTTTCTGGAC 237 68–60 TD, 1M B
MPG 1 GGTCCTAGGGGTGCTTCC TGGCCTATGCTCTGGCTCT 254 68–60 TD, 1.7M B
2A GCTGTCTCCTATTCGGATGC CCCTTTGGGCTTGAGAAATA 248 68–60 TD, 1.7M B
2B CACACAGCTCGTCCGATG CAGTGACAGGCACTTCAGGA 229 68–60 TD, 1M B
3A TGGGCACTGTTAGGGTGAGT ACCCTGGCTGGAGATGTTC 273 68–60 TD, 1M B
3B CTAGTCCGGCGACTTCCTAA CCCCACCTCAGTCCTCCTA 291 68–60 TD, 1M BBMC Cancer 2006, 6:243 http://www.biomedcentral.com/1471-2407/6/243
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4A GCAGAGAGGACAGGAGCCTA CCAGCCATACAGCTTCATCC 267 68–60 TD, 1M B
4B GAGACCATGCGTCAGCTTC ACATAGAAGCGGAGGGGTTT 266 68–60 TD, 1M B
4C GATGAAGCTGTATGGCTGGAG GCTCTGGCTAAGGCACAGTT 270 68–60 TD, 1M B
TDG 1 TCTCTGGGGTTGTCTTACCG AGCCTGCCCAGCAGTGAG 180 68–60 TD, 1M B
2 TGATCATTTGGATTTACATTTGG GGCTGATCCGATGTTGAACT 252 68–60 TD, 1M B
3A TTTTCTGGGAAAGCTGCTAAA GGGGAGAGTCTTGGTCAGAA 279 60–50 TD
3B CTGGCAAGTCTGCAAAATCA GGTCCTTTTCAGCAAAATGC 252 60–50 TD
4 GATGAAATGTCTAATTGTTTTGTT
TT
CACACAGAACATGAAACACGA 233 60–50 TD
5 GGCTGCACTGAGCCATGAT GGTTCCAACCCATAAAAGCA 271 68–50 TD
6 TCAAGCTGAGCTCAACAAATG CAAACATATTTACATTGCCCATAA 262 68–60 TD





300 60–50 TD, 1M B
8B CATCCAGTGCAAGATGTGCT CACAAAATGAATAAAAGGAATGAG
G
190 68–60 TD, 1M B
9 CAAGAAAAAGAATTGTTCATGATT
TC
CCTGACCAAACCGTCTTTGA 267 68–60 TD
10 GGCGATAGAGTAAGACCCAGTC GGTTCTACTTGTTGACAACTGCAT 298 68–60 TD
UNG 1 AATTGCTGACCGCCACAG CCTTCCTCCCCCTTCACC 262 68–60 TD, 1M B
2A GGGCTCTTACTGTCCGCTTT CTCTGGATCCGGTCCAACT 240 68–60 TD, 1M B
2B GACCACTTGCAGGCCATC GGCCGGCTACACTAACAAGA 296 68–60 TD, 1M B
3 TTGAATTCTTATGGTTTCCAATGA TGTGGCTTAACTCCAGTGTCC 240 68–60 TD, 1M B
4 CAGGGTCTGTGCTGCTTACA AACAGTGCCCCAGATAGTCC 251 68–60 TD, 1M B
5A CAAGGGCTGGCTGTAACTTC TAGCAGTCGCTGGCTTACCT 218 68–60 TD, 1M B
5B GGCTTGCTTTCAGTTTGGAG CAGCTATGGTGGCTCATGC 288 68–60 TD, 1M B
6 TGCCTGAGCCTACATTTAACC GCAGGGACTCCTAGAATTCTTTA 299 60–50 TD, 1M B
7 CCACTGCAGCAAGACTCTGT GGAACTTCGTAACTGGCAAA 60–50 TD
SMUG
1
1A CTCTGTGGCTGAGGGTTGAT TTGTAGATGATGCCCACAGG 233 68–50 TD, 1M B
1B AGAGCTTCCTGGAGGAGGAG AGCCAAGCATCCACCTAGAA 258 68–60 TD, 1M B
2A TCTCCAGTTTGAAGCCTTTCAT CTCAGCAGGAGTAAGGTTGC 300 68–60 TD, 1M B
2B CCACAATCTATGCCCTCTGC TCAATCTTTCCTTGGCCACT 296 68–60 TD, 1M B
2C TCTTGGGATCTGTGATGCAG TTCGAGGTCTTGAATGTGTCC 286 68–60 TD, 1M B
* TD, Touchdown °C; B, Betaine
Table 3: Sequences of primers and PCR conditions used to screen BER genes. (Continued)BMC Cancer 2006, 6:243 http://www.biomedcentral.com/1471-2407/6/243
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Discussion
We have sought to identify pathogenic germline muta-
tions in seven genes encoding components of the BER sys-
tem. To empower our analysis we have studied familial
cases in which involvement of the known CRC predispo-
sition genes has been excluded. In ascertaining familial
cases we have relied on reported information. While inac-
curacy in reported family histories is a theoretic limita-
tion, studies have shown that cancers such as CRC are
generally reliably reported in first-degree relatives [17].
While MYH associated polyposis is an autosomal reces-
sive disease we purposely did not restrict our analysis to
individuals with these phenotypes as there is no evidence
a priori that mutations in other BER will operate in a sim-
ilar fashion, hence it is appropriate to consider all models
of inheritance. None of the patients studied harboured
clearly pathogenic biallelic sequence variants, nor was
there strong evidence that any single variant was disease
causing.
We cannot exclude the possibility that a minority of muta-
tions have been missed, but under test conditions we have
found that CSGE can detect all small insertions or dele-
tions and 70% of single base substitutions. Here the tech-
nique detected a number of single base substitution
polymorphisms hence there is over a 90% probability that
an allele conferring a 2-fold increase in CRC risk with a
population frequency = 1% will have been identified
through screening the 94 familial cases. Based on the
number of patients we have screened for constitutive
mutations we can conclude with 95% probability that
germline variation in any of these genes will at best not
account for more than 3% of all familial CRCs in the Brit-
ish population (upper 95% confidence interval of point
estimate).
We detected a number of novel germline alterations in
NEIL2, TDG, UNG genes in patients with CRC. Three
novel missense variants detected in familial CRC cases
were predicted to be probably damaging by both the
Polyphen and SIFT algorithms. While these algorithms
have been demonstrated in benchmarking studies to suc-
cessfully categorise 80% of amino acid substitutions [18],
predictions about the functional consequences of amino
acid changes are not definitive and require validation in
functional assays. Overall results suggest at best a limited
role for these variants in predisposition.
The substrates of the BER glycosylases overlap and there-
fore there is functional redundancy within the oxidative
DNA damage repair system. On this basis it is perhaps not
surprising that we did not identify disease causing muta-
tions in our study. Such an assertion does not however,
take into account the fact that mutation of MUTYH is
causative of CRC. Finally, our current analyses do not
exclude the possibility that sequence variants in the genes
we analysed are associated with low penetrance CRC sus-
ceptibility. Evaluation of this hypothesis will require addi-
tional studies comparing the frequency of gene sequence
variants in large series of CRC cancer cases and healthy
controls.
Conclusion
We report here the first NEIL2, TDG, UNG germline alter-
ations in patients with CRC. However, the rarity of such
alterations suggests a limited role for sequence variation
in defining predisposition. Notwithstanding, germline
variants in these genes do exist and may be associated
with susceptibility, but further studies including func-
tional analyses are needed for confirmation.
Abbreviations
APC, adenomatosis polyposis coli; BER, base excision
repair; CRC, colorectal cancer; CSGE, conformation sensi-
tive gel electrophoresis; MMR, mismatch repair; MPG, N-
@methylpurine DNA glycosylase; MUTYH, MutY, E.coli,
homolog of; NEIL1, endonuclease VIII-like 1; NEIL2,
endonuclease VIII-like 2; NSCCG, National Study of
Colorectal Cancer; NTHL1, endonuclease III-like 1; ROS,
reactive oxygen species; SMUG1, single-strand-selective
monofunctional uracil-dna glycosylase 1; TDG, thymine-
DNA glycosylase; UNG, uracil-DNA glycosylase
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
PB, TB, JV, SL and IC carried out the genetic studies. PB
and RSH were responsible for drafting and revising the
manuscript. PB and RSH were involved in design of the
study, providing important intellectual content and
acquisition of the study material. All authors read and
approved the final manuscript.
Acknowledgements
We are grateful to all the study participants and their clinicians. Funding for 
this work was supported by grants from Cancer Research UK. The 
NSCCG is supported by NCRN (National Cancer Research Network) and 
CORE.
References
1. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Kosken-
vuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and her-
itable factors in the causation of cancer--analyses of cohorts
of twins from Sweden, Denmark, and Finland.  N Engl J Med
2000, 343(2):78-85.
2. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Wil-
liams GT, Hodges AK, Davies DR, David SS, Sampson JR, Cheadle JP:
Inherited variants of MYH associated with somatic G:C--
>T:A mutations in colorectal tumors.  Nat Genet 2002,
30(2):227-232.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:243 http://www.biomedcentral.com/1471-2407/6/243
Page 7 of 7
(page number not for citation purposes)
3. Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips RK,
Bisgaard ML, Orntoft TF, Aaltonen LA, Hodgson SV, Thomas HJ,
Tomlinson IP: Multiple colorectal adenomas, classic adenoma-
tous polyposis, and germ-line mutations in MYH.  N Engl J Med
2003, 348(9):791-799.
4. Slupska MM, Luther WM, Chiang JH, Yang H, Miller JH: Functional
expression of hMYH, a human homolog of the Escherichia
coli MutY protein.  J Bacteriol 1999, 181(19):6210-6213.
5. Ames BN, Gold LS: Endogenous mutagens and the causes of
aging and cancer.  Mutat Res 1991, 250(1-2):3-16.
6. Huycke MM, Gaskins HR: Commensal bacteria, redox stress,
and colorectal cancer: mechanisms and models.  Exp Biol Med
(Maywood) 2004, 229(7):586-597.
7. National Study of Colorectal Cancer Genetics Trial.   [http://
www.ncrn.org.uk/portfolio/data.asp?ID=1269]
8. Royal Marsden Hospital Trust/Institute of Cancer Research
Family History and DNA Registry.   [http://intra-test.icr.ac.uk/
tissueres/patient_blood.html]
9. University of California Santa Cruz (UCSC) Human
Genome Browser   [http://genome.ucsc.edu/cgi-bin/hgGateway]
10. Primer3   [http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi]
11. Ganguly A, Rock MJ, Prockop DJ: Conformation-sensitive gel
electrophoresis for rapid detection of single-base differences
in double-stranded PCR products and DNA fragments: evi-
dence for solvent-induced bends in DNA heteroduplexes.
Proc Natl Acad Sci U S A 1993, 90(21):10325-10329.
12. Polymorphism Phenotyping (PolyPhen)   [ h t t p : / /
www.bork.embl-heidelberg.de/PolyPhen/]
13. Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs:
server and survey.  Nucleic Acids Res 2002, 30(17):3894-3900.
14. Sorting Intolerant from Tolerant (SIFT)   [ h t t p : / /
blocks.fhcrc.org/sift/SIFT.html]
15. Ng PC, Henikoff S: Predicting deleterious amino acid substitu-
tions.  Genome Res 2001, 11(5):863-874.
16. National Center for Biotechnology Information (NCBI)
dbSNP Database.  [http://wwwncbinlmnihgov/SNP/];  .
17. Kerber RA, Slattery ML: Comparison of self-reported and data-
base-linked family history of cancer data in a case-control
study.  Am J Epidemiol 1997, 146(3):244-248.
18. Xi T, Jones IM, Mohrenweiser HW: Many amino acid substitution
variants identified in DNA repair genes during human popu-
lation screenings are predicted to impact protein function.
Genomics 2004, 83(6):970-979.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/243/pre
pub